M
Marisa Dolled-Filhart
Researcher at Merck & Co.
Publications - 83
Citations - 17293
Marisa Dolled-Filhart is an academic researcher from Merck & Co.. The author has contributed to research in topics: Pembrolizumab & Lung cancer. The author has an hindex of 34, co-authored 83 publications receiving 14187 citations. Previous affiliations of Marisa Dolled-Filhart include University of California, Los Angeles & Netherlands Cancer Institute.
Papers
More filters
Journal ArticleDOI
Pembrolizumab for the treatment of non-small cell lung cancer
Edward B. Garon,Naiyer A. Rizvi,Rina Hui,Natasha B. Leighl,Ani Sarkis Balmanoukian,Joseph Paul Eder,Amita Patnaik,Charu Aggarwal,Matthew A. Gubens,Leora Horn,Enric Carcereny,Myung-Ju Ahn,Enriqueta Felip,Jong-Seok Lee,Matthew D. Hellmann,Omid Hamid,Jonathan W. Goldman,Jean-Charles Soria,Marisa Dolled-Filhart,Ruth Z. Rutledge,Jin Zhang,Jared Lunceford,Reshma A. Rangwala,Gregory M. Lubiniecki,Charlotte Roach,Kenneth Emancipator,Leena Gandhi +26 more
TL;DR: Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer and PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolIZumab.
Journal ArticleDOI
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S. Herbst,Paul Baas,Dong Wan Kim,Enriqueta Felip,Jose Luis Perez-Gracia,Ji Youn Han,Julian R. Molina,Joo Hang Kim,Catherine Dubos Arvis,Myung-Ju Ahn,Margarita Majem,Mary J. Fidler,Gilberto de Castro,Marcelo Garrido,Gregory M. Lubiniecki,Yue Shentu,Ellie Im,Marisa Dolled-Filhart,Edward B. Garon +18 more
TL;DR: In this article, the authors evaluated the efficacy of pembrolizumab for patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer.
Journal ArticleDOI
X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization
TL;DR: A graphical method is developed, the X-tile plot, that illustrates the presence of substantial tumor subpopulations and shows the robustness of the relationship between a biomarker and outcome by construction of a two dimensional projection of every possible subpopulation.
Journal ArticleDOI
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
Laura Q.M. Chow,Robert I. Haddad,Shilpa Gupta,Amit Mahipal,Ranee Mehra,Makoto Tahara,Raanan Berger,Joseph Paul Eder,Barbara Burtness,Se-Hoon Lee,Bhumsuk Keam,Hyunseok Kang,Kei Muro,Jared Weiss,Ravit Geva,Chia-Chi Lin,Hyun Cheol Chung,Amy Meister,Marisa Dolled-Filhart,Kumudu Pathiraja,Jonathan D. Cheng,Tanguy Y. Seiwert +21 more
TL;DR: Fixed-dose pembrolizumab 200 mg administered once every 3 weeks was well tolerated and yielded a clinically meaningful ORR with evidence of durable responses, which supports further development of this regimen in patients with advanced HNSCC.
Journal ArticleDOI
Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
Adil Daud,Jedd D. Wolchok,Caroline Robert,Wen-Jen Hwu,Jeffrey S. Weber,Antoni Ribas,F. Stephen Hodi,Anthony M. Joshua,Richard F. Kefford,Richard F. Kefford,Richard F. Kefford,Peter Hersey,Richard W. Joseph,Tara C. Gangadhar,Roxana S. Dronca,Amita Patnaik,Hassane M. Zarour,Charlotte Roach,Grant Toland,Jared Lunceford,Xiaoyun Nicole Li,Kenneth Emancipator,Marisa Dolled-Filhart,S. Peter Kang,Scot Ebbinghaus,Omid Hamid +25 more
TL;DR: PD-L 1 expression in pretreatment tumor biopsy samples was correlated with response rate, PFS, and OS; however, patients with PD-L1-negative tumors may also achieve durable responses.